32 results about "Peptide formation" patented technology

A method for the manufacture of an oat peptide isolate, the oat peptide isolate comprising at least 80% w / w peptides, and less than 0.1% w / w total soluble fibre. The method comprises combining an oat protein concentrate having a protein concentration of at least 40% w / w with an enzyme capable of facilitating carbohydrate hydrolysis, removing the sugar fraction, and combining with an enzyme capable of peptide formation.

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating psoriasis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of 'CD177 + neutrophil-NETs' of psoriasis, the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the precise targeting function of CD177 peptide and the NETs inhibition function of a PADI4 inhibitor are creatively and organically integrated, and the constructed GNLC achieves the synergistic treatment effect of 'targeting enrichment-mechanism blocking-microenvironment remodeling'; meanwhile, excellent stability and safety are achieved, and a new precise treatment strategy far better than that in the prior art is provided for psoriasis.

An object of the present invention is to provide a cell aggregate-inducing peptide, a cell aggregate-forming agent containing the same, and a method for forming a cell aggregate using the same.SOLUTION: A cell aggregate-inducing peptide represented by General Formula (1), having hydroxypipecolic acid and lysine as constituent repeating units. (HPA-Lys) n. (1) [In the general formula (1), HPA represents hydroxypipecolic acid, Lys represents lysine, and n is an integer of 4 or more and 30 or less.]. ] SELECTED DRAWING: None

The invention discloses an electrochemical sensor for glycoprotein detection and a glycoprotein detection method. The method comprises the following steps: anchoring an aptamer-protein conjugate on the surface of a gold electrode, and then assembling an anti-fouling peptide around the aptamer-protein conjugate to form an imprinted self-assembled monolayer film. And removing the combined protein through an acid solution to form a biocompatible imprinting cavity capable of being used for recombining a target object. The imprinted cavity can eliminate non-specific adsorption and enhance targeted binding efficiency. The sensor can be used for directly detecting carcino-embryonic antigens with the concentration as low as 0.1 ng / mL through an electrochemical impedance spectroscopy method. Besides, homodimer concanavalin A (ConA) is used as a recognition element and a cross-linking agent, homodimer glucose oxidase (GOx) is assembled on the surface of the electrode in situ, a protein network can be formed, and enzyme catalysis signal amplification detection is achieved. Through in-situ formation of a ConA-GOx assembly, the sensitivity is improved by 100 times.

The invention relates to a fibrous protein ELISA (enzyme-linked immunosorbent assay) detection method based on homing peptide combined with malachite green, which comprises the following steps: S1, synthesizing a template chain and homing peptide to form a sensing probe; s2, adding a to-be-detected solution containing fibrin into an antibody solution to obtain a fibrin-antibody compound, and adding a sensing probe, a first primer and a second primer for incubation; s3, adding a first lock-type probe and a second lock-type probe for catalytic cyclization; s4, carrying out synchronous rolling circle transcription to obtain long-chain RNA respectively containing M1 and M2 sequence fragments; and S5, adding malachite green dye for incubation, and triggering a fluorescence signal. Compared with the prior art, by means of target fibrin mediation, dual recognition of the integrated antibody and the homing peptide on fibrin and signal generation induced by the split type MG-RNA aptamer, background noise is remarkably reduced, and specificity is remarkably improved.

The invention discloses probucol nano targeting particles as well as application and a pharmaceutical composition thereof, and relates to the technical field of pharmacy. The probucol nano targeting particle comprises a polymer formed by Poly (HPDMA-RSM)-PEG-NHS and a kidney targeting peptide, wherein the sequence of the kidney targeting peptide is KCSAVPLC, and the sequence of the kidney targeting peptide is KCSAVPLC. And probucol; wherein in the probucol nanometer targeting particle, the hydrophobic segment of the polymer and probucol are aggregated to form a solid core, the hydrophilic PEG chain of the polymer extends outwards to form a hydration shell layer, and the kidney targeting peptide is exposed on the surface of the probucol nanometer targeting particle. According to the invention, Probucol is encapsulated in PEG nanoparticles coupled with KTP for the first time, so that (1) accurate enrichment of renal tubular epithelium is realized; (2) the ferroptosis pathway is efficiently inhibited; (3) the curative effect is obviously improved. The strategy shows a synergistic protection effect superior to that of a naked drug and other antioxidants in a cis-platinum induced AKI model, and has outstanding creativity and industrial transformation value.

The present invention relates to a method for forming a conjugate of a desired target substance and a peptide. A method according to the present invention includes a step for bringing a genetic information material-linker-peptide conjugate into contact with a target substance conjugate containing at least two target substances. The genetic information material-linker-peptide conjugate includes: (a) a linker that includes a bond portion having a structure capable of binding to a desired genetic information material and includes at least two puromycin-like substances, the puromycin-like substances being capable of covalently binding to the C-terminus of a desired peptide; (b) a genetic information material that is bonded to the bond portion of the linker of (a); and (c) a peptide that is bonded to at least two or more puromycin-like substances of the linker of (a) and is encoded by the genetic information material.

The invention provides iron binding peptides based on tuna blood combined meat. The amino acid sequences of some polypeptides are SEQ ID NO: 1-6. The polypeptide provided by the invention can be used for preparing a product for treating iron-deficiency anemia. According to the tuna red meat hematopoietin provided by the invention, an organic iron compound with high bioavailability is formed through the chelation of specific polypeptide iron ions in preparation of a blood replenishing product, so that the absorption efficiency of intestinal tracts on iron is remarkably improved. A carrier formed by the polypeptide can protect iron ions from being damaged by gastric acid, and the iron ions are delivered to an absorption part in a targeted mode, so that the hemoglobin synthesis efficiency is improved by 40% or above. The natural polypeptide ligand disclosed by the invention avoids gastrointestinal irritation of a traditional iron supplementing agent, and is not interfered by absorption of dietary factors such as phytic acid and tannin. The tuna processing by-product is used as the raw material to prepare the functional blood-enriching peptide, so that high-value utilization of fishery resources is realized, and an eco-friendly new iron-enriching source is provided.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The structure of the CD177 targeting membrane modified lipidosome is divided into three layers, and comprises a lipidosome loaded with a PADI4 inhibitor, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the lipidosome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. In an imiquimod (IMQ)-induced lupus model, the medicine treatment shows strong disease remission capability: 1) improving the whole body phenotype: obviously reducing the swollen spleen and lymph node of lupus mice; 2) repairing kidney functions: significantly relieving glomerulonephritis, and reducing inflammatory cell infiltration and IgG and complement C3 deposition in glomerulus, and 3) significantly reducing the level of proinflammatory cytokines in serum and the titer of a lupus marker anti-dsDNA antibody.

The invention provides a tumor whole tissue-derived antigen polypeptide tumor nano vaccine and a preparation method thereof. The preparation method of the vaccine comprises the following steps: (1) extracting tumor whole tissue antigen polypeptide by a high-temperature hydrothermal method; and (2) forming a polypeptide-BSA compound and preparing the nano vaccine by using an ethanol-protein precipitation method. The preparation method of the vaccine is simple and suitable for batch preparation and production; the antigen presentation efficiency can be effectively improved by adopting a nano vaccine form; the material can be derived from individual patients to realize personalized treatment.

This invention discloses a system for rapid detection of tumor cell invasiveness and risk level reference based on matrix remodeling fluorescence reporter assay. After staining, test cells are seeded on a matrix material formed by cell adhesion ligands and fluorescent dye-modified polyisocyanate peptides for 2D culture, or the two components are thoroughly mixed and gelled to form a 3D culture environment, resulting in a cell-induced matrix remodeling fluorescence detection system. Fluorescence images of the area surrounding the sample are acquired, and cell invasiveness risk is analyzed based on changes in the intensity of the fluorescence signal in the surrounding area and the matrix remodeling index. This invention provides a more direct and rapid assessment of tumor cell invasiveness by observing the matrix remodeling characteristics induced during cell invasion in real time in vitro, providing a risk level reference for tumor malignancy.

In various aspects, the present disclosure provides methods for forming radiopaque peptides that comprise one or more iodinated amino acid residues and one or more amine-based amino acid residues. Typically, the peptides contain from 3 to 20 amino acid residues. The present disclosure relates to methods of forming such radiopaque peptides, to the use of such radiopaque peptides as crosslinking agents for forming hydrogels, and to hydrogels formed from such radiopaque peptides. The radiopaque peptides and hydrogels are useful, for example, in various medical applications.

Disclosed herein are peptides compounds which are capable of forming collagen mimetic biomaterials. In some embodiments, the presently disclosed peptides may be stabilized by cation-pi interactions or by covalent interactions involving levodopa residues. In some embodiments, the present disclosure provides higher order structures formed from the peptides disclosed herein, including homotrimers, heterotrimers, and hydrogels.

Triple G-C-T base coded nucleobase amino acids according to Formula (I):wherein R is —H or -Boc, are provided as building blocks for peptide sequences. The compound of formula (I) includes three recognition sites, DDA (G mimic), DAA (C mimic) and ADA (T mimic) that can simultaneously interact with two sets of nucleobases (C-A or G-A), at any given time. A one-step synthetic process for the triple G-C-T base coded nucleobase amino acids is provided.

In various aspects, the present disclosure provides methods for forming radiopaque peptides that comprise one or more iodinated amino acid residues and one or more amine-based amino acid residues. Typically, the peptides contain from 3 to 20 amino acid residues. The present disclosure relates to methods of forming such radiopaque peptides, to the use of such radiopaque peptides as crosslinking agents for forming hydrogels, and to hydrogels formed from such radiopaque peptides. The radiopaque peptides and hydrogels are useful, for example, in various medical applications.

To provide a novel method that forms a complex linking a peptide with DNA encoding the peptide to establish correspondence therebetween, and to provide a method for readily selecting DNA encoding a desired peptide from a complex library in which peptides correspond to DNA encoding the peptides.SOLUTION: A method for creating a complex in which a peptide is linked to a nucleotide sequence encoding the peptide, the method comprising: (1) preparing circular DNA having a nucleotide sequence encoding a peptide; and (2) transcribing and translating the nucleotide sequence from the circular DNA using a cell-free transcription-translation reaction to express a peptide, wherein the expressed peptide forms a complex linked to the circular DNA.SELECTED DRAWING: None

The invention discloses a polymer protein nanoparticle and application thereof in preparation of a novel coronavirus broad-spectrum vaccine, and the polymer protein nanoparticle is prepared by forming a pentamer compound FP-HR5 fusion protein by using heptapeptide repeat regions HR1 and HR2 and a fusion peptide FP on a coronavirus S protein, and on the basis, assembling with Ferritin to obtain the polymer protein nanoparticle. And preparing the novel coronavirus antigen polymer compound FP-HR5-NP protein nanoparticles. The novel coronavirus universal nanoparticle vaccine which can be inoculated through injection or a respiratory system and has a good immune protection effect is prepared by taking the coronavirus as an immunogen. The obtained novel coronavirus vaccine is good in immune protection effect, mucosal immunity can be remarkably activated after a respiratory system is inoculated, infection of novel coronaviruses of different mutant strains can be avoided after the respiratory system is inoculated, the preparation method is simple, the protein expression and purification technical route is mature, safety is high, and the novel coronavirus vaccine can be rapidly applied to clinical tests.

This invention discloses a membrane-modified liposomal drug targeting CD177-positive neutrophils and its preparation method. The membrane-modified liposomal drug has a three-layer structure, including: a liposome loaded with a PADI4 inhibitor, a targeting recognition layer formed by coupling a CD177 targeting peptide to the surface of the liposome, and an outermost biomimetic functional layer formed by coating the natural neutrophil membrane. Based on the key pathological mechanism of the "CD177-NETs axis," this invention designs a structurally sound, safe, and stable biomimetic targeted nanoformulation. It creatively combines the anti-inflammatory / chemotactic function of the neutrophil membrane, the precise targeting of the CD177 peptide to pathogenic subgroups, and the source blocking of NETs by the PADI4 inhibitor, achieving highly efficient dual-targeted enrichment and synergistic therapy.

The invention relates to the technical field of biological materials, and particularly provides a coating for modifying a mouth rehabilitation material, application and the mouth rehabilitation material.The coating for modifying the mouth rehabilitation material is formed by adsorbing cationic oligopeptide on the surface of the mouth rehabilitation material, the amino acid sequence of the cationic oligopeptide comprises H (K) nS, and n is 1-20. The coating for modifying the dental restoration material has good binding capacity to materials such as zirconium oxide, zirconium phosphate or titanium, so that biological activity modification of inert materials such as zirconium oxide, phosphorylated zirconium oxide or titanium or zirconium phosphate serving as surface components is possible, and the coating has a wide application prospect.

This invention belongs to the field of environmental monitoring and analytical chemistry technology, and provides a rapid detection method and kit for polystyrene microplastics based on a sandwich method. It includes: a capture component, a magnetic bead-peptide conjugate with a specific peptide covalently coupled to it; and a detection component, a luminescent detection probe formed by covalently coupling bovine serum albumin with a chemiluminescent label and the specific peptide; the specific peptide has an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. The peptide of this invention possesses extremely strong specific binding ability, which can reduce cross-reactions by precisely matching the microplastic target structure, thereby improving detection specificity from the root cause; the use of magnetic beads to load the peptide, with the ultra-large specific surface area of ​​the magnetic beads, can significantly improve the binding efficiency between the peptide and the microplastic; combined with the luminescent group or fluorescent group coupled to the peptide, no additional enzyme-labeled secondary antibody incubation and enzyme-catalyzed colorimetric reaction are required.

The present application relates to the technical field of biological materials, and specifically provides a coating for modifying an oral repair material, application and oral repair material, wherein the coating for modifying the oral repair material is formed by adsorbing cationic short peptides on the surface of the oral repair material, and the amino acid sequence of the cationic short peptides comprises H(K)nS, wherein n is 1-20.The coating for modifying the oral repair material has good binding capacity for materials such as zirconium oxide, zirconium phosphate or titanium, thereby making it possible to modify the biological activity of materials such as zirconium oxide, zirconium phosphate, zirconium oxide or titanium or inert materials such as zirconium phosphate on the surface, and having a wide application prospect.

The present disclosure provides a method of predicting a structure of an interface between a target peptide and a targeting peptide. The method leverages test pairs of variants of a target peptide and variants of a targeting peptide and their binding affinities measured by a high-throughput analysis. Synergistic pairs among the test pairs are selected and multiple sequence alignment (MSA) of the selected pairs is performed to predict a structure of the protein complex formed with the target peptide and the targeting peptide. Structure prediction using MSA of the synergistic pairs provides for improved results, thereby paving the path for downstream analyses, e.g., small molecule design for molecular glues or antibody design.

A modified fibrous electrode having associated therewith a self-assembled structure formed of a plurality of short aromatic peptides and a biocatalyst associated with the self-assembled structure, electrochemical cells and systems assembled with such modified electrodes and uses thereof are provided.

The antibodies of the present invention have specific binding activity to HLA-DQ2.5 and may have binding activity to HLA-DQ2.2 and / or HLA-DQ7.5, but substantially no binding activity to HLA-DQ8, HLA-DQ5.1, HLA-DQ6.3, HLA-DQ7.3, HLA-DR, HLA-DP, or a complex of the invariant chain (CD74) and HLA-DQ2.5. The antibodies bind to HLA-DQ2.5 in the presence of a gluten peptide such as gliadin, i.e., bind to HLA-DQ2.5 forming a complex with the gluten peptide. The antibodies have neutralizing activity against the binding between HLA-DQ2.5 and TCR, and thus block the interaction between HLA-DQ2.5 and an HLA-DQ2.5-restricted CD4+ T cell. The antibodies do not undergo rapid internalization mediated by the invariant chain.

To provide a compound of formula (I): A-B-C (I) (where, A is a hydrophobic moiety; B is a peptide, the peptide forming a β-sheet; and C is a hydrophilic targeting ligand, the hydrophilic targeting ligand being a LLP2A prodrug, LLP2A, LXY30, LXW64, DUPA, folate, a LHRH peptide, a HER2 ligand, an EGFR ligand, or a toll-like receptor agonist CpG oligonucleotides).SOLUTION: The present invention also provides nanocarriers comprising compounds of the present invention, nanofibril formation from the nanocarriers, and methods of using the nanocarriers for treating diseases and imaging.SELECTED DRAWING: None

The present disclosure provides descriptions of compositions and methods for the production of glycoconjugate polypeptides using a glycosidic bond forming enzyme that then forms an isopeptide bond with a second polypeptide containing a polypeptide tag, as well as the use of the glycoconjugate polypeptides.

The present disclosure provides a method of predicting a structure of an interface between a target peptide and a targeting peptide. The method leverages test pairs of variants of a target peptide and variants of a targeting peptide and their binding affinities measured by a high-throughput analysis. Synergistic pairs among the test pairs are selected and multiple sequence alignment (MSA) of the selected pairs is performed to predict a structure of the protein complex formed with the target peptide and the targeting peptide. Structure prediction using MSA of the synergistic pairs provides for improved results, thereby paving the path for downstream analyses, e.g., small molecule design for molecular glues or antibody design.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of RA 'CD177 + neutrophil-NETs', the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the synovial membrane pathogenic cell precise targeting function of CD177 peptide and the NETs source blocking function of a PADI4 inhibitor are creatively and organically integrated; the constructed GNLC realizes a synergistic treatment effect of joint targeted enrichment-pathological mechanism blocking-synovial microenvironment remodeling, and also has excellent stability and long-term safety.

The present invention provides anti-HLA-DQ2.5 antibodies. These antibodies have binding activity against complexes formed between HLA-DQ2.5 and gluten peptides, but have little binding activity against complexes formed between HLA-DQ2.5 and unrelated peptides. Furthermore, the antibodies have been found to inhibit T cell activation.